Immunome Inc.
IMNM Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$17.99
KIRA · Stoqly’s AI analyst, in plain words
- Immunome Inc. had $6.9M of revenue in fiscal 2025, down 23.2% on the year before.
- Its operating margin was −3,228.8%, up 153.5 pts: of every 100 in sales, about −3,229 is left after running the business.
- Immunome Inc. lost $212M in fiscal 2025.
- Free cash flow was −$201M in fiscal 2025, −2,890.1% of revenue.
Market cap
$2.0B
P/E
—
Revenue
$6.9M
Net income
−$212M
Free cash flow
−$201M
Operating margin
−3,228.8%
Immunome Inc. in 30 seconds · fiscal 2025
Are sales growing?
−23.2%
No. Sales fell 23.2% last year.
Does it make a profit?
−3,060.0%
No. It lost money last year.
Does profit turn into cash?
−2,890.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Immunome Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- Immunome Inc.
- CIK
- 0001472012
Immunome Inc. · IMNM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$0.0M | $0.0M | $14.0M | $9.0M | $6.9M |
| Revenue growth | — | — | 280,260.0% | −35.5% | −23.2% |
| Net interest income | −$0.0M | $0.0M | $2.7M | $12.8M | $11.7M |
| Operating margin | 252,040.0% | −738,020.0% | −781.4% | −3,382.4% | −3,228.8% |
| Net income | −$24.7M | −$36.9M | −$107M | −$293M | −$212M |
| Net margin | 247,110.0% | −737,920.0% | −761.9% | −3,240.4% | −3,060.0% |
| Diluted EPS | −$2.14 | −$3.09 | −$5.38 | −$5.00 | −$2.43 |
| Cash | |||||
| Cash from operations | −$18.2M | −$28.7M | −$7.6M | −$111M | −$191M |
| Capital expenditure | $0.1M | $0.2M | $0.8M | $7.2M | $9.7M |
| Free cash flow | −$18.3M | −$28.9M | −$8.4M | −$118M | −$201M |
| FCF margin | 183,050.0% | −578,760.0% | −59.9% | −1,304.8% | −2,890.1% |
| Share count change | 240.4% | 5.1% | 63.6% | 195.5% | 49.0% |
| Debt and strength | |||||
| Cash and short-term investments | $49.2M | $20.3M | $138M | $217M | $653M |
| Shareholders' equity | $48.2M | $16.7M | $120M | $181M | $634M |
| Current ratio | 5.8x | 3.1x | 6.6x | 4.1x | 14.7x |
| Returns and quality | |||||
| Return on equity | −55.2% | −113.8% | −156.5% | −194.6% | −52.1% |
| Return on tangible equity | −51.3% | −225.3% | −89.1% | −161.7% | −33.5% |
| Piotroski F-score | 2 | 2 | 4 | 1 | 3 |
| Altman Z'' | 3.1 | −19.5 | −0.0 | −7.8 | 13.9 |
Insiders bought, 12 months
$2.3M
3 insiders
Insiders sold, 12 months
$27.5M
7 insiders
Of sales under plans
94%
$26.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Immunome Inc. · IMNM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $17.99 a share, the company is worth $2.0B.
Source: SEC EDGAR XBRL filings (CIK 0001472012). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.